about
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerPhase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies.A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies.Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer.Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.Emerging role of topotecan in first-line therapy of small-cell lung cancer.A Phase I trial of protracted oral fixed-dose temozolomide.Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.Phase II trial of vinflunine in relapsed small cell lung cancer.A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.The addition of granulocyte-colony stimulating factor shifts the dose limiting toxicity and markedly increases the maximum tolerated dose and activity of the kinesin spindle protein inhibitor SB-743921 in patients with relapsed or refractory lymphomA phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.Diagnosis, staging, and clinical characteristics of the patient with mediastinal germ cell carcinoma.Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.Phase I. Trial of irinotecan plus carboplatin in two dose schedules.Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours.Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.Prolonging remission with rituximab maintenance therapy.Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
P50
Q27860681-E4F8B83B-E98A-4C86-ABF6-5F8A39CB459FQ33342389-93DF65F0-8404-4FC9-939F-BC34732435A6Q33344974-2856DD65-E670-464B-A855-9DEA18BC81FFQ33346674-5CD04EAD-DD87-430E-910A-62A86BFA1560Q33347969-37635D8F-59FE-48BC-9A20-B3E65B77885BQ33348462-A0EBCEA0-4CA3-4513-921A-7DE49906E546Q33357517-19C29F7E-1BAD-494D-B1AF-8DF0B4C8D48CQ33368231-005FE2C0-67D0-427B-A6C0-5454F4958C0FQ33371058-82E07AE7-253E-4DB4-B32C-6F44437F681EQ33376534-A8D66B4F-0DFC-4AD2-BE5B-36D84250AACCQ33376934-BEF8302C-F66A-46EA-8AA6-F003C2B1FADAQ33379947-0B1BF027-3C1A-454F-9BC3-B0B429D9903DQ33384992-07154A4A-D9B1-4E8D-9A5E-29248B149056Q33386878-66910830-45B4-4324-AF0A-6C47EA9C3BB5Q33388297-1538B3C0-9F3A-45A6-A378-813E2CEE5C4CQ33389883-6B55505E-2BB3-4600-B601-9D3FD8EDF4C6Q33389889-47BEFCA3-CBD5-4802-A9E1-05A0F8573DFAQ33395740-84F72672-45F1-42A9-8932-487B8987D355Q33397076-FCD40B7A-7E21-42CB-969F-B0DF1F6E7B74Q33403116-274DF8CA-E8DA-40DE-AD9E-AECE6BD7A731Q33405544-72ABFCE7-D7E2-486B-8EEC-54F2B0322E50Q33420259-A898C984-1221-4A1D-9BD7-DC9060BE2C31Q33433136-9EE9E0D2-FB0A-409A-8862-987E7269011DQ33433377-9A6671B7-5CB6-4560-82B2-49FEC6750A53Q33645191-6818D5A5-C9B0-4630-8CA4-2D587CD7EAFEQ33651496-87E3E2DD-7393-4CCA-B386-D18B2BA97489Q33880538-9D49B0F2-EF03-4BA6-96E5-EF9F484C44EFQ33901988-BD22BB95-31F8-4879-BECC-2BA80929ED4FQ34050239-005D2327-AFCF-4780-8307-585F1022CDFCQ35020125-B64CBABB-58E3-493B-A46C-5E66027D69ECQ35024740-FAC82D9F-B6A9-47FE-B8C4-5DABA896BB1BQ35090601-738E722D-BBCC-482E-9694-5E0153F392CDQ35151456-AC5396F0-1242-42BB-9CB4-C617F134AC3FQ35552871-345220A2-C18A-4927-96DC-53CF0CABC5D6Q35563529-C974B63B-DA57-4B09-8B48-9AA941B52080Q35571044-03F7730F-F9BD-4403-AE37-7D86056DB3D5Q35584067-F047141C-8B87-40B9-9E73-B837BF4887C7Q35602123-82449217-3D57-4745-97D1-EB04BE7A95F5Q35712427-E3D5D1D8-1D93-43AB-814B-C78832792F13Q35794369-B027C178-F79D-4D3B-977B-09BDA5367B03
P50
name
John D Hainsworth
@en
John D Hainsworth
@nl
type
label
John D Hainsworth
@en
John D Hainsworth
@nl
prefLabel
John D Hainsworth
@en
John D Hainsworth
@nl